Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
CC transcript
Asset disposition
Appointed director
CTI BIOPHARMA CORP (CTI) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/30/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders"
05/10/2023 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...
Docs: "Agreement and Plan of Merger, among CTI BioPharma Corp., Swedish Orphan Biovitrum AB (publ) and Cleopatra Acquisition Corp",
"CTI BioPharma Corp.’s Amended and Restated Bylaws",
"Tender and Support Agreement, among Swedish Orphan Biovitrum AB (publ), Cleopatra Acquisition Corp. and certain stockholders of CTI BioPharma Corp",
"Sobi to Acquire CTI BioPharma"
03/06/2023 8-K Quarterly results
Docs: "CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results – Growing physician awareness and usage of VONJO® drove quarterly double-digit revenue growth –"
11/07/2022 8-K Quarterly results
Docs: "CTI BioPharma Reports Third Quarter 2022 Financial Results – VONJO® net product revenue of $18.2 million in the third quarter, a 48% increase compared to the second quarter –"
10/13/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
09/28/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CTI BioPharma Corporate Presentation Slides"
08/15/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/31/2022 8-K Quarterly results
Docs: "CTI BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results – VONJOTM Approved by FDA for the Treatment of Adult Myelofibrosis Patients with Myelofibrosis and Thrombocytopenia&#59; Commercial Launch Underway –"
03/04/2022 8-K Quarterly results
03/01/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CTI BioPharma Announces FDA Accelerated Approval of VONJO ™ for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia"
08/25/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
08/24/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
06/07/2021 8-K Quarterly results
06/01/2021 8-K Quarterly results
04/06/2021 8-K Quarterly results
03/17/2021 8-K Quarterly results
01/15/2021 8-K Quarterly results
11/10/2020 8-K Quarterly results
Docs: "CTI BioPharma Reports Third Quarter 2020 Financial Results – Rolling NDA Submission for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia Initiated in October –"
09/29/2020 8-K Quarterly results
08/06/2020 8-K Quarterly results
06/10/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "CTI BioPharma Corp. Amended and Restated 2017 Equity Incentive Plan"
05/07/2020 8-K Quarterly results
04/22/2020 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
04/13/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "AMENDED AND RESTATED BYLAWS OF CTI BIOPHARMA CORP. a Delaware corporation ARTICLE I REGISTERED OFFICE 1.1 Delaware Office. The Corporation shall have and maintain a registered office in the State of Delaware as required by law. The name and address of its registered agent in the State of Delaware is set forth in the Certificate of Incorporation of the Corporation . 1.2 Other Offices. The Corporation may have such other offices, either within or without the State of Delaware, as the Board of Directors of the Corporation may designate or as the business of the Corporation may from time to time require. ARTICLE II STOCKHOLDER MEETINGS 2.1 Meeting Place. All meetings of the stockholders shall be held, pursuant to proper notice as set forth in Section 2.4 of this Article II, at the principal ex..."
03/12/2020 8-K Quarterly results
03/06/2020 8-K Quarterly results
02/14/2020 8-K Quarterly results
02/03/2020 8-K Investor presentation
Docs: "CTI BioPharma Corp. Presentation"
02/03/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Investment Agreement",
"CTI BioPharma Announces Proposed Rights Offering Rights Offering will be Available to All Stockholders of Record on February 13, 2020 $60 million expected to be raised; fully backstopped by BVF Partners L.P., Stonepine Capital, L.P., OrbiMed Private Investments VI, LP, and New Enterprise Associates, Inc."
12/05/2019 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "Letter from Nasdaq Listing Qualifications Department",
"Letter from Nasdaq Listing Qualifications Department"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy